U-S 181 (Divalproex sodium delayed-release 250 mg)

Pill imprint U-S 181 has been identified as Divalproex sodium delayed-release 250 mg.

Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; hyperekplexia; epilepsy (and more), and belongs to the drug class fatty acid derivative anticonvulsants. When treating epilepsy and manic episodes associated with bipolar disorder: There is positive evidence of human fetal risk during pregnancy. When treating migraine: Not for use in pregnancy. Divalproex sodium 250 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for U-S 181

Divalproex sodium delayed-release 250 mg U-S 181
Divalproex sodium delayed-release
Imprint:
U-S 181
Strength:
250 mg
Color:
Beige
Size:
15.00 mm
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Fatty acid derivative anticonvulsants
Pregnancy Category:
D - Positive evidence of risk - When treating epilepsy and manic episodes associated with bipolar disorder
X - Not for use in pregnancy - When treating migraine
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Upsher-Smith Laboratories, Inc
National Drug Code (NDC):
00245-0181
Inactive Ingredients:
methacrylic acid - ethyl acrylate copolymer (1:1) type a
povidone
corn starch
silicon dioxide
sodium bicarbonate
sodium lauryl sulfate
magnesium silicate
triethyl citrate
titanium dioxide
vanillin
FD&C Yellow No. 6
ferric oxide red

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web4)